NCT00782717 - A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Macular Edema

Interventions

DRUG

Nepafenac ophthalmic suspension, 0.1% (NEVANAC)

1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.

OTHER

Nepafenac ophthalmic suspension vehicle

1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

DRUG

Prednisolone acetate ophthalmic suspension (OMNIPRED)

One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.